Molecular biology of myeloma N. C. GutiérrezR. García-SanzJ. F. San Miguel Educational Series 18 November 2007 Pages: 618 - 624
Signalling pathways involved in clinical responses to chemotherapy R. PeronaI. Sánchez-Pérez Educational Series 18 November 2007 Pages: 625 - 633
Pharmacodynamics: biological activity of targeted therapies in clinical trials F. RojoA. DalmasesJ. Albanell Educational Series 18 November 2007 Pages: 634 - 644
Impact of erythropoietin treatment on the quality of life of oncologic patients A. Pelegrí Review 18 November 2007 Pages: 645 - 651
Treatment of peritoneal carcinomatosis from ovarian cancer. Present, future directions and proposals F. C. Muñoz-CasaresS. RufiánA. Gómez-Portilla Special Article 18 November 2007 Pages: 652 - 662
Can the clinical outcome in state II colon carcinomas be predicted by determination of molecular marker expression? J. M. Fernández-CebriánM. Nevado SantosM. Ramos Fernández Research Articles 18 November 2007 Pages: 663 - 670
Sorafenib TARGET Trial results in Spanish patients J. BellmuntJ. L. González-LarribaJ. Albanell Research Articles 18 November 2007 Pages: 671 - 673
Glucagonoma with two pancreatic masses and pulmonary metastases as debut of MEN-1 V. GutiérrezM. CoboJ. Alcalde Case Reports 18 November 2007 Pages: 674 - 677
Intrahepatic mucinous biliary cystadenoma A. Díaz de LiañoE. OliveraH. Ortiz Case Reports 18 November 2007 Pages: 678 - 680